

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM809121

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
OXFORD FINANCE LLC		05/04/2023	Limited Liability Company: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	NovaQuest Co-Investment Fund X, L.P.		
<b>Street Address:</b>	4208 Six Forks Road, Suite 920		
<b>City:</b>	Raleigh		
<b>State/Country:</b>	NORTH CAROLINA		
<b>Postal Code:</b>	27609		
<b>Entity Type:</b>	Limited Partnership: DELAWARE		
<b>PROPERTY NUMBERS Total: 10</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	5024098	NEVAKAR	
<b>Registration Number:</b>	5128464	REPOSITIONING DRUGS FOR A BETTER OUTCOME	
<b>Registration Number:</b>	5466189	QUALITY WITHOUT BORDERS	
<b>Registration Number:</b>	6702564	NUPHARMING	
<b>Registration Number:</b>	6199967	MYMYOPIA.COM	
<b>Registration Number:</b>	6607569	VYLUMA	
<b>Serial Number:</b>	90865247	MYLUMO	
<b>Serial Number:</b>	97663849	EYALTA	
<b>Serial Number:</b>	97663824	EYVERI	
<b>Serial Number:</b>	97663182	OPTRU	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	9197814865		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	919.882.7143		
<b>Email:</b>	ip@wyrick.com		
<b>Correspondent Name:</b>	Devon E. White		
<b>Address Line 1:</b>	4101 Lake Boone Trail, Suite 300		
<b>Address Line 2:</b>	Wyrick Robbins Yates & Ponton LLP		

OP \$265.00 5024098

**Address Line 4:** Raleigh, NORTH CAROLINA 27607

**NAME OF SUBMITTER:** Devon E White

**SIGNATURE:** /dew/

**DATE SIGNED:** 05/09/2023

**Total Attachments: 9**

source=NovaQuest - Assignment of Intellectual Property Security Agreement (Oxford Finance LLC)#page1.tif  
source=NovaQuest - Assignment of Intellectual Property Security Agreement (Oxford Finance LLC)#page2.tif  
source=NovaQuest - Assignment of Intellectual Property Security Agreement (Oxford Finance LLC)#page3.tif  
source=NovaQuest - Assignment of Intellectual Property Security Agreement (Oxford Finance LLC)#page4.tif  
source=NovaQuest - Assignment of Intellectual Property Security Agreement (Oxford Finance LLC)#page5.tif  
source=NovaQuest - Assignment of Intellectual Property Security Agreement (Oxford Finance LLC)#page6.tif  
source=NovaQuest - Assignment of Intellectual Property Security Agreement (Oxford Finance LLC)#page7.tif  
source=NovaQuest - Assignment of Intellectual Property Security Agreement (Oxford Finance LLC)#page8.tif  
source=NovaQuest - Assignment of Intellectual Property Security Agreement (Oxford Finance LLC)#page9.tif

**ASSIGNMENT OF INTELLECTUAL PROPERTY SECURITY AGREEMENT**

THIS ASSIGNMENT OF INTELLECTUAL PROPERTY SECURITY AGREEMENT (this “**Assignment**”), dated as of May 4, 2023, is by OXFORD FINANCE LLC, a Delaware limited liability company (“**Oxford Finance**”), acting in its capacity as the current and assigning collateral agent (in such capacity, the “**Assignor Agent**”), and NovaQuest Co-Investment Fund X, L.P., a Delaware limited partnership (“**NovaQuest**”), acting in its capacity as the assignee collateral agent (in such capacity, the “**Assignee Agent**”).

WHEREAS, Nevakar Inc., a Delaware corporation, Vyluma Inc., a Delaware corporation, and Nevakar Injectables Inc., a Delaware corporation, collectively, as “**Grantor**”, and Assignor Agent are parties to that certain Intellectual Property Security Agreement, dated as of January 10, 2023 (as amended, restated, supplemented or otherwise modified from time to time, the “**Agreement**”) covering certain intellectual property set forth on **Exhibits A, B, C, and D** attached hereto; and

WHEREAS, pursuant to that certain Assignment of Loans, Liens and Loan Documents by and among Oxford Finance, as the Assignor Agent and a lender, NovaQuest, and certain other parties thereto, dated as of the date hereof, Assignor Agent has assigned to Assignee Agent all of its rights, remedies, duties and other obligations under, among other documents, the Agreement, in each instance, in its capacity as collateral agent under the Agreement.

NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor Agent hereby assigns and transfers to Assignee Agent and its successors and assigns, all of its rights, title and interest in and to the Agreement.

This Assignment may be executed in any number of counterparts, each of which when so executed shall be deemed an original and all of which taken together shall constitute one and the same instrument.

*(Remainder of page left intentionally blank; signatures follow.)*

**IN WITNESS WHEREOF**, Assignor Agent and Assignee Agent have caused this Assignment to be duly executed as of the date first above written.

**ASSIGNOR AGENT:**

OXFORD FINANCE LLC

By: \_\_\_\_\_

Name: Colette H. Featherly

Title: Senior Vice President

**ASSIGNEE AGENT:**

NOVAQUEST CO-INVESTMENT FUND X, L.P.

By: NQ POF V GP, Ltd., its general partner

By: \_\_\_\_\_

John L. Bradley, Jr., Director

IN WITNESS WHEREOF, Assignor Agent and Assignee Agent have caused this Assignment to be duly executed as of the date first above written.

**ASSIGNOR AGENT:**

OXFORD FINANCE LLC

By: \_\_\_\_\_


Name: \_\_\_\_\_

Title: \_\_\_\_\_

**ASSIGNEE AGENT:**

NOVAQUEST CO-INVESTMENT FUND X, L.P.

By: NQ POF V GP, Ltd., its general partner

By:  \_\_\_\_\_  
John L. Bradley, Jr., Director

**EXHIBIT "A"**

Copyrights

None.

**EXHIBIT “B”**

Patents

<u>Owner</u>	<u>Description</u>	<u>Patent/App. No.</u>	<u>File Date</u>	<u>Jurisdiction</u>
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 10251875	10 May 2018	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 10568875	20 February 2019	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 10583132	20 February 2019	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 10610525	20 February 2019	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 10576074	20 February 2019	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 11071732	20 February 2019	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 11464769	20 July 2020	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 17007816	31 August 2020	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 17007900	31 August 2020	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 17016186	9 September 2020	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 17145589	11 January 2021	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	US 17685286	2 March 2022	USA
Vyluma Inc.	Atropine Pharmaceutical Compositions	3,063,228	10 May 2018	Canada
Vyluma Inc.	Ophthalmic Atropine Compositions	JP 6557379	10 May 2018	Japan
Vyluma Inc.	Ophthalmic Atropine Compositions	JP 6865476	10 May 2018	Japan
Vyluma Inc.	Ophthalmic Atropine Compositions	JP 6681502	11 July 2019	Japan
Vyluma Inc.	Ophthalmic Atropine Compositions	JP 6681503	11 July 2019	Japan
Vyluma Inc.	Ophthalmic Atropine Compositions	2021-56894	11 July 2019	Japan
Vyluma Inc.	Atropine Pharmaceutical Compositions	3548000	8 July 2019	Europe
Vyluma Inc.	Atropine Pharmaceutical Compositions	21205568.5	29 October 2021	Europe
Vyluma Inc.	Atropine Pharmaceutical Compositions	AU 2018265257	25 October 2019	Australia
Vyluma Inc.	Atropine Pharmaceutical Compositions	NZ 758555	25 October 2019	New Zealand
Vyluma Inc.	Atropine Pharmaceutical Compositions	BR 1120190235159	25 October 2019	Brazil
Vyluma Inc.	Atropine Pharmaceutical Compositions	392558	25 October 2019	Mexico
Vyluma Inc.	Atropine Pharmaceutical Compositions	11201910085U	25 October 2019	Singapore
Vyluma Inc.	Atropine Pharmaceutical Compositions	1-2019-06890	6 December 2019	Vietnam
Vyluma Inc.	Atropine Pharmaceutical Compositions	10-2281667	6 December 2019	Korea
Vyluma Inc.	Atropine Pharmaceutical Compositions	IDP000082353	29 November 2019	Indonesia
Vyluma Inc.	Atropine Pharmaceutical Compositions	40310	28 November 2019	Colombia
Vyluma Inc.	Atropine Pharmaceutical Compositions	201903228	11 November 2019	Chile
Vyluma Inc.	Atropine Pharmaceutical Compositions	2745603	11 December 2019	Russia
Vyluma Inc.	Atropine Pharmaceutical Compositions	2019/19945	11 December 2019	Turkey
Vyluma Inc.	Atropine Pharmaceutical Compositions	201927047383	20 November 2019	India
Vyluma Inc.	Atropine Pharmaceutical Compositions	1-2019-502701	28 November 2019	Philippines
Vyluma Inc.	Atropine Pharmaceutical Compositions	110621298 B	11 November 2019	China
Vyluma Inc.	Atropine Pharmaceutical Compositions	42022058129	9 April 2020	Hong Kong
Vyluma Inc.	Multi-dose Container for Ophthalmic Compositions	PCT/US22/20246	14 March 2022	PCT Countries
Vyluma Inc.	Childhood Atropine for Myopia Progression	US 63414779	10 October 2022	USA
Vyluma Inc.	Childhood Atropine for Myopia Progression	US 63419650	26 October 2022	USA
Vyluma Inc.	Childhood Atropine for Myopia Progression	US 63419675	26 October 2022	USA
Vyluma Inc.	TOAST Abstract	US 63348256	2 June 2022	USA
Vyluma Inc.	TOAST Poster	US 63402374	30 August 2022	USA
Vyluma Inc.	Low-Dose Carbachol Ophthalmic Compositions With Cumulative Effect	PCT/IB2022/054864	25 May 2022	PCT Countries
Vyluma Inc.	Low-Dose Carbachol Compositions And Methods For Treatment Of Night Vision Disturbance	US 11273141	18 May 2021	USA
Vyluma Inc.	Low-Dose Carbachol Compositions And Methods For Treatment Of Night Vision Disturbance	US 17/591,944	3 February 2022	USA

Owner	Description	Patent/App. No.	File Date	Jurisdiction
Vyluma Inc	Low-Dose Carbachol Compositions And Methods For Treatment Of Night Vision Disturbance	21809576.8	11 November 2022	Europe
Vyluma Inc	Low-Dose Carbachol Compositions And Methods For Treatment Of Night Vision Disturbance	3,178,254	8 November 2022	Canada
Vyluma Inc	Low-Dose Ophthalmic Compositions and Methods	PCT/US21/43061	23 July 2021	PCT Countries
Vyluma Inc	Methods and Formulation for Topical Administration of Gabapentenoids	PCT/US2022/017997	25 February 2022	PCT Countries
Nevakar Injectables Inc.	Norepinephrine Compositions and Methods Therefor	US 10226436	30 January 2018	USA
Nevakar Injectables Inc.	Norepinephrine Compositions and Methods Therefor	US 10159657	10 April 2018	USA
Nevakar Injectables Inc.	Norepinephrine Compositions and Methods Therefor	US 10471026	17 October 2018	USA
Nevakar Injectables Inc.	Norepinephrine Compositions and Methods Therefor	US 10420735	17 October 2018	USA
Nevakar Injectables Inc.	Norepinephrine Compositions and Methods Therefor	US 10646458	3 January 2018	USA
Nevakar Injectables Inc.	Norepinephrine Compositions and Methods Therefor	US 10568850	3 January 2018	USA
Nevakar Injectables Inc.	Norepinephrine Compositions and Methods Therefor	US 11413259	3 April 2020	USA
Nevakar Injectables Inc.	Norepinephrine Compositions and Methods Therefor	US 17861752	11 July 2022	USA
Nevakar Injectables Inc.	Norepinephrine Compositions and Methods Therefor	US 17872450	25 July 2022	USA
Nevakar Injectables Inc.	Norepinephrine Compositions and Methods Therefor	3,051,467	24 July 2019	Canada
Nevakar Injectables Inc.	Vancomycin Liposome Composition and Methods	US 17612551	18 November 2021	USA
Nevakar Injectables Inc.	Vancomycin Liposome Composition and Methods	JP 2021-570935	26 November 2021	Japan
Nevakar Injectables Inc.	Vancomycin Liposome Composition and Methods	EP20813948.5	28 October 2021	Europe
Nevakar Injectables Inc.	Formulations for Treating Pain	US 10052296	21 August 2018	USA
Nevakar Injectables Inc.	Formulations for Treating Pain	US 10,874,626	05 October 2018	USA
Nevakar Injectables Inc.	Formulations for Treating Pain	US 17/098,923	16 November 2020	USA
Nevakar Injectables Inc.	Acetaminophen-Pregabalin Combinations and Methods of Treating Pain	11,547,686	2 April 2020	USA
Nevakar Injectables Inc.	Acetaminophen-Pregabalin Combinations and Methods of Treating Pain	18/076,264	6 December 2022	USA
Nevakar Injectables Inc.	Acetaminophen-Pregabalin Combinations and Methods of Treating Pain	18864043.7	30 April 2020	Europe
Nevakar Injectables Inc.	Acetaminophen-Pregabalin Combinations and Methods of Treating Pain	3075414	9 March 2020	Canada
Nevakar Injectables Inc.	Acetaminophen-Pregabalin Combinations and Methods of Treating Pain	2018800783614.00	3 June 2020	China
Nevakar Injectables Inc.	Acetaminophen-Pregabalin Combinations and Methods of Treating Pain	2020-518795	1 April 2020	Japan
Nevakar Injectables Inc.	Fixed Dose Composition Formulations for Treating Pain	16/644,022	3 March 2020	USA



Owner	Description	Patent/App. No.	File Date	Jurisdiction
Nevakar Injectables Inc.	Fixed Dose Composition Formulations for Treating Pain	18860180.1	12 March 2020	Europe
Nevakar Injectables Inc.	Liquid Unit Dosage Forms for Treatment of Postoperative Pain	PCT/US22/16636	16 February 2022	PCT Countries
Nevakar Injectables Inc.	Injectable Pregabalin Formulations	PCT/US2022/031982	2 June 2022	PCT Countries
Nevakar Injectables Inc.	Methods For Reducing Catecholamine-Formaldehyde Adducts	18/011,664	20 December 2022	USA
Nevakar Injectables Inc.	Injectable Compositions of Vitamers of Vitamin B12 and Uses Thereof	US 63/314724	28 February 2022	USA
Nevakar Injectables Inc.	Injectable Compositions of Vitamers of Vitamin B12 and Uses Thereof	US 63/314724	28 February 2022	USA
Nevakar Injectables Inc.	Succinylcholine Prefilled Syringe, Compositions and Methods	US 10682308	11 February 2019	USA
Nevakar Injectables Inc.	Succinylcholine Prefilled Syringe, Compositions and Methods	US 10722453	31 March 2020	USA
Nevakar Injectables Inc.	Succinylcholine Prefilled Syringe, Compositions and Methods	US 10722454	31 March 2020	USA
Nevakar Injectables Inc.	Succinylcholine Prefilled Syringe, Compositions and Methods	US 10722455	31 March 2020	USA
Nevakar Injectables Inc.	Succinylcholine Prefilled Syringe, Compositions and Methods	US 16909340	23 June 2020	USA
Nevakar Injectables Inc.	Ephedrine Compositions and Methods	US 10,869,845	22 January 2020	USA
Nevakar Injectables Inc.	Ephedrine Compositions and Methods	US 11,491,121	12 November 2020	USA
Nevakar Injectables Inc.	Ephedrine Compositions and Methods	US 17/960,343	5 October 2022	USA
Nevakar Injectables Inc.	Epinephrine Compositions and Methods	US 10,653,646	21 March 2019	USA
Nevakar Injectables Inc.	Epinephrine Compositions and Methods	US 11,071,719	12 February 2020	USA
Nevakar Injectables Inc.	Epinephrine Compositions and Methods	US 11,207,280	17 March 2020	USA
Nevakar Injectables Inc.	Epinephrine Compositions and Methods	US 11,083,698	17 March 2020	USA
Nevakar Injectables Inc.	Epinephrine Composition and Containers	US 17/526,786	15 November 2021	USA
Nevakar Injectables Inc.	Epinephrine Compositions and Containers	3093725	21 March 2019	Canada

**EXHIBIT "C"****Trademarks**

<u>Owner</u>	<u>Description</u>	<u>Serial/ Registration No.</u>	<u>File Date</u>	<u>Jurisdiction</u>
Nevakar	NEVAKAR	5,024,098	August 16, 2016	US
Nevakar	REPOSITIONING DRUGS FOR A BETTER OUTCOME	5,128,464	January 24, 2017	US
Nevakar	QUALITY WITHOUT BORDERS	5,466,189	May 8, 2018	US
Vyluma	MyMyopia.com	6,199,967	November 1, 2020	US
Nevakar	NuPharming	6,702,564	April 12, 2022	US
Vyluma	Mylumo	90,865,247	August 4, 2021	US, Peru, Hong Kong, Argentina, UK, New Zealand, WIPO # (1,681,020)
Vyluma	Eyalta	Applic. #97663849	November 4, 2022	US
Vyluma	Eyveri	Applic. #97663824	November 4, 2022	US
Vyluma	Optm	Applic. #97663182	November 4, 2022	US
Vyluma	Vyluma	6,607,569	February 18, 2021	US

**EXHIBIT "D"**

Mask Works

None.